Table 2.

Univariable Analysis of Overall Survival

Variable	n	1-y, %	95% CI	2-y, %	95% CI	p Value
Age
18–59	317	58	(53–64)	42	(36–48)	0.0044
60–69	477	57	(52–61)	37	(32–42)
≥70	391	49	(44–54)	32	(27–37)
Sex
Men	527	49	(44–53)	31	(27–35)	<0.0001
Women	658	60	(56–63)	42	(37–46)
WHO performance score
0	444	65	(61–70)	46	(41–51)	<0.0001
1	518	50	(46–54)	32	(28–37)
≥2	99	39	(30–49)	32	(23–42)
Unknown	124	48	(39–56)	25	(16–34)
Number of metastatic organs
1	501	64	(59–68)	46	(41–51)	<0.0001
2	341	55	(50–60)	35	(29–41)
≥3	343	41	(36–46)	25	(21–31)
PD-L1
0%	317	41	(36–46)	20	(16–26)	<0.0001
1%–49%	292	55	(49–61)	35	(29–41)
50%–89%	378	59	(54–64)	45	(39–50)
≥90%	198	67	(60–73)	50	(42–58)
Year
2019	572	57	(52–61)	38	(34–42)	0.3329
2020	613	53	(49–57)	-	(-)
KRAS
KRAS G12C	494	57	(53–62)	35	(30–40)	0.6683
KRAS non-G12C	691	53	(49–56)	38	(34–42)
Treatment
Chemoimmunotherapy	735	50	(47–54)	31	(28–35)	<0.0001
Monoimmunotherapy	450	62	(57–66)	46	(41–51)

CI, confidence interval; PD-L1, programmed death-ligand 1.